title: Frequent phosphorylation at serine 392 in overexpressed p53 protein due to missense mutation in carcinoma of the urinary tract.
abstract: Post-transcriptional modification of p53 by phosphorylation has been proposed to be an important mechanism of p53 stabilization and functional regulation. Phosphorylation of p53 Ser392, in particular, activates specific DNA binding functions by stabilizing p53 tetramer formation. This study evaluated the relationship between p53 Ser392 phosphorylation and various types of p53 missense mutation detected in urothelial transitional cell carcinomas (TCCs), with stratification of the mutations according to the functional domains elucidated by the crystal structure of the p53 protein. Of 41 TCCs with missense mutations, 26 (63.4%) exhibited immunopositivity with Ser392 phospho-specific p53 antibody. In comparison to structural mutations, the missense mutations at exon 7 (p=0.0307) or located in regions that affect direct DNA binding ability (p = 0.0273) were significantly associated with Ser392 immunopositivity. No statistically significant relationship was found between Ser392 immunoreactivity and other different types of p53 mutation. The prevalence of cases exhibiting Ser392-positive immunostaining was higher for high-grade (p <0.0001) and advanced-stage TCCs (p =0.0119) than for TCCs with wild-type p53. No significant relationship was found between Ser392 immunoreactivity and apoptotic index in urothelial TCCs. These in vivo findings indicate that Ser392 phosphorylation frequently occurs in mutant form p53 in TCCs. Because mutant form p53 can act dominant-negatively by heterooligomerization with wild-type p53, these findings also suggest that Ser392 phosphorylation might activate tetramer formation to promote the dominant-negative effects of mutant form p53, and thereby contribute to proliferation of aggressive TCCs.
authors.affiliation: Department of Pathology II, Kochi Medical School, Nankoku, Japan. furihata@kochi-ms.ac.jp
authors.forename: Mutsuo
authors.initials: M
authors.lastname: Furihata
authors.forename: Atsushi
authors.initials: A
authors.lastname: Kurabayashl
authors.forename: Manabu
authors.initials: M
authors.lastname: Matsumoto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sonobe
authors.forename: Yuji
authors.initials: Y
authors.lastname: Ohtsuki
authors.forename: Naotami
authors.initials: N
authors.lastname: Terao
authors.forename: Morimasa
authors.initials: M
authors.lastname: Kuwahara
authors.forename: Taro
authors.initials: T
authors.lastname: Shuin
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D017209:Apoptosis; D002295:Carcinoma, Transitional Cell / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D005260:Female; D016158:Genes, p53; D006801:Humans; D008297:Male; D008875:Middle Aged; D020125:Mutation, Missense; D010766:Phosphorylation; D012694:Serine / Q000235:genetics*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*; D014571:Urologic Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology
chemical_list: D016159:Tumor Suppressor Protein p53; D012694:Serine